SCHEMBL358516

SCHEMBL358516

COc1ccc(Nc2cnc3ccc(Br)cc3c2N)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.66
NCOA1 Q15788 1/20 0.66
NCOA3 Q9Y6Q9 1/20 0.66
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 4/20 0.46
HTT P42858 2/20 0.46
RAB9A P51151 2/20 0.45
GAK O14976 2/20 0.44
RIPK2 O43353 2/20 0.44
COQ8A Q8NI60 2/20 0.44
NLK Q9UBE8 2/20 0.44
EPHB6 O15197 1/20 0.44
STK16 O75716 1/20 0.44
ABL1 P00519 1/20 0.44
ACVR1 Q04771 1/20 0.44
AAK1 Q2M2I8 1/20 0.44
EGFR P00533 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358426 0.85 NPC1 (0.65) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2
SCHEMBL358801 0.76 NPC1 (0.59) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2
SCHEMBL26086336 0.75 GAK (0.65) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2
SCHEMBL30880614 0.72 GAK (0.65) NPC1NCOA1NCOA3MAPTGAK
SCHEMBL2254291 0.72 TNF (0.47) NPC1ALDH1A1SMN1; SMN2HPGDMAPT
SCHEMBL439635 0.71 APP (0.48) ALDH1A1MAPK1MAPTEGFRMEN1
SCHEMBL30849390 0.70 MAPT (0.49) NPC1NCOA1NCOA3SMN1; SMN2MAPT
SCHEMBL29207180 0.70 MAPT (0.49) NPC1NCOA1NCOA3SMN1; SMN2MAPT
SCHEMBL28158163 0.70 AKR1C3 (0.58) NPC1NCOA1NCOA3ALDH1A1HPGD
SCHEMBL5929807 0.69 CSF1R (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 NPC1 3676/4885NCOA1 776/4885NCOA3 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.